3672
541540
SOLARA
As of the latest trading session, SOLARA ACTIVE PHA SCI LTD share price is currently at ₹ 592.9, which is up by ₹ 2.40 from its previous closing. Today, the stock has fluctuated between ₹ 582.45 and ₹ 599.80. Over the past year, SOLARA ACTIVE PHA SCI LTD has achieved a return of -20.85 %. In the last month alone, the return has been 6.64 %. Read More...
Smart Investing Starts here !
Trade Smart with Fast Execution & Zero Account Opening Fees
Invest Now
| Particulars | SEP 2025 (Values in Cr) |
|---|---|
| Revenue | 313.54 |
| Operating Expense | 324.10 |
| Net Profit | -10.08 |
| Net Profit Margin (%) | -3.21 |
| Earnings Per Share (EPS) | -2.36 |
| EBITDA | 35.23 |
| Effective Tax Rate (%) | 0.00 |
| Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
|---|---|---|---|---|---|
| AMBALAL SARABHAI ENTERPRISES L | 28.97 | 14.20 | 1.50 | 222.01 | 25.97 / 67.90 |
| BLISS GVS PHARMA LTD | 144.15 | 13.91 | 1.34 | 1524.95 | 105.05 / 190.65 |
| CIPLA LTD | 1517.20 | 22.52 | 3.72 | 122555.05 | 1310.05 / 1672.20 |
| FERMENTA BIOTECH LIMITED | 340.35 | 8.94 | 2.56 | 1001.68 | 219.00 / 449.00 |
| Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
|---|---|---|---|---|---|
| AMBALAL SARABHAI ENTERPRISES L | 28.97 | 23.55 | 4.03 | 222.01 | 25.97 / 67.90 |
| AMRUTAJAN HEALTH LTD | 689.65 | 35.17 | 5.82 | 1993.82 | 548.05 / 829.00 |
| ASTRAZENECA PHARMA IND LT | 9138.35 | 98.83 | 28.59 | 22845.88 | 6301.00 / 10653.05 |
| BLISS GVS PHARMA LTD | 144.15 | 19.45 | 1.38 | 1524.95 | 105.05 / 190.65 |
Choose a Plan That Suits Your Goals and Needs
For Q1 of FY 25-26, the company's consolidated sales were ₹319 crore, and its net profit for the period stood at ₹11 crore. In the corresponding Q1 of FY 24-25, the sales were ₹363 crore with a net loss of ₹13 crore for the period.
Date Source: screener.in, and corporate filings on NSE/BSE
For FY 24-25, the company reported consolidated sales of ₹1,284 crore and a net profit of ₹1 crore. In the preceding year, FY 23-24, the company's sales were ₹1,289 crore with the net loss of ₹567 crore.
Date Source: screener.in, and corporate filings on NSE/BSE
The company's stock has a face value of ₹10.0 per share and pays a dividend yield of 0.00%. The company has not declared any dividend in recent years. The last dividend of ₹3 was issued for FY 2021-22 with an ex-date of August 18, 2021.
Date Source: screener.in, and corporate filings on NSE/BSE
Solara Active Pharma Sciences Limited was founded on February 23, 2017, and its main business is making and selling active pharmaceutical ingredients (APIs). An API is the main part of a completed medicine that makes it work the way it is supposed to for treatment. Solara is a pure-play API producer, which means that its main business is making these important chemicals for other pharmaceutical businesses that subsequently turn them into medications like tablets, capsules, and injections. The corporation makes APIs for the worldwide market, processes them, sells them, imports them, and exports them.
The company operates six API production locations in important industrial districts in India: Ambernath in Maharashtra, Mangalore and Mysuru in Karnataka, Puducherry, Visakhapatnam in Andhra Pradesh, and Cuddalore in Tamil Nadu. These facilities together have more than 2,580 kilolitres of reactor capacity, which is enough for their needs for large-scale manufacturing. In addition to being able to create things, the corporation has two research and development (R&D) facilities, one in Chennai and the other in Bengaluru. In the API industry, these centres need to come up with new goods and create better methods to do things. It has more than 25 products in varying stages of development in its research and development pipeline.
Solara has more than 80 different APIs in its commercial portfolio. These APIs are grouped by therapeutic area. It has made a name for itself in some market categories, such as anthelmintics (drugs that cure parasitic worm diseases) and anti-malarials (drugs that treat and prevent malaria). Some of the other areas of attention are anti-infectives, muscle relaxants, medications for neuromuscular insomnia, anti-psychotics, and therapies for hyperkalaemia, which is when there is too much potassium in the blood. Its pharmaceutical development pipeline is also focused on these and other speciality markets, such as beta-blockers and new oral anticoagulants.
National and regional health authorities must provide their clearance before people may access highly controlled overseas marketplaces. Many important regulatory bodies from all around the world have looked at and approved Solara's manufacturing facilities. The USFDA, the EDQM, Japan's PMDA, and Australia's TGA are among these. The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, the World Health Organisation (WHO) in Geneva, and the KFDA in South Korea and Cofepris in Mexico have all also given their permission. With these certifications, the company may sell its APIs to pharmaceutical companies that do business in these important worldwide markets.
The company's corporate structure has been changed by a number of key events. It purchased all of Strides Chemicals Private Limited's equity in 2018, making it a wholly owned subsidiary. After that, the two companies merged, and Strides Chemicals officially became part of Solara. The merger took effect in February 2020. The firm built a new greenfield factory in a Special Economic Zone (SEZ) near Visakhapatnam, Andhra Pradesh, to increase its production capacity. This new plant started making things for sale in 2021.
In April 2021, Solara bought further shares in Sequent Penems Private Limited, making it a fully owned subsidiary and letting it join the penem class of antibiotics. But subsequently, the company sold this asset as part of a change in strategy. In April 2024, it sold all of its shares in Sequent Penems Private Limited to Symbio Generics India Private Limited. After the sale, Sequent Penems was no longer a part of Solara.
1. Who is the CEO of Solara Active Pharma Sciences Ltd?
The CEO of Solara Active Pharma Sciences Ltd is Poorvank Purohit, who also serves as the Managing Director of the company.
2. When was Solara Active Pharma Sciences Ltd established?
Solara Active Pharma Sciences Ltd was incorporated on February 23, 2017. The company was formed from the demerger of the Active Pharmaceutical Ingredients (API) business from Strides Shasun Ltd.
3. What factors influence the Solara Share Price?
The Solara share price is influenced by factors such as financial performance, market conditions, regulatory approvals, and the global demand for active pharmaceutical ingredients. Changes in debt levels, profit margins, and strategic moves like the sale of its stake in Sequent Penems also impact its share price.
4. Is Solara Active Pharma Sciences Ltd debt-free?
No, Solara Active Pharma Sciences Ltd is not debt-free. As of March 2024, the company reported borrowings of Rs. 1,012 crores. However, it has been actively working to reduce its working capital requirements over time.
5. What is the CAGR of Solara Share?
The Compound Annual Growth Rate (CAGR) of Solara’s stock price over the past five years stands at 13%. However, the three-year CAGR is negative at -7%, reflecting a decline in the stock’s value during that period.
6. How has the Solara Share Price performed over the past year?
Over the past year, Solara’s share price has seen a significant increase, rising by 143%, demonstrating a positive market response despite challenges in revenue and profitability.
Solara Active Pharma Sciences Limited was incorporated on February 23, 2017 to undertake business in manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of and dealing in active pharmaceutical ingredients (APIs). The Company has 6 APIs manufacturing plants located in Ambernath, Mangalore, Mysuru, Puducherry, Vishakhapatnam, and Cuddalore with a capacity of over 2,580 kilo litres and two R&D Centres in Chennai and Bengaluru.
The Company offer rich basket of niche high-value products for global markets. The Company has developed 80+ commercial APIs predominantly in anthelmintic, anti-malarias, anti-infective, neuromuscular insomnia and anti-psychotic hyperkalemia segments, among others. These drugs primarily deal with anthelmintic, anti-malarias, beta blockers, muscle relaxants, novel oral anticoagulants, anti-infective and other niche segments.
The Company's manufacturing facilities enjoy regulatory approvals from the United States Food and Drug Administration (USFDA); European Directorate for the Quality of Medicines (EDQM); Korea Food & Drug Administration (KFDA) - South Korea; Euro Zone - Good Manufacturing Practice (EUGMP) - Danish, World Health Organization (WHO) - Geneva; Medicines and Healthcare products Regulatory Agency (MHRA); Federal Commission for the Protection against Sanitary Risk (Cofepris) - Mexico; Therapeutic Goods Administration (TGA) - Australia; Pharmaceuticals and Medical Devices Agency (PMDA) - Japan.
The Company acquired 100% of the equity shares of Strides Chemicals Private Limited and made it the wholly owned subsidiary of the Company effective from September 1, 2018. During the year 2018-19, the Company's wholly owned subsidiary Strides Chemicals Private Limited amalgamated with the Company on December 20, 2019 and the merger was given effect in February, 2020.
The Company's new Greenfield plant situated at SEZ unit, Plot No.:3B,3C,3D, Part 2 and 2A-1, APIIC APSEZ, Atchutapuram Village, Rambilli Mandal, Visakhapatnam - 531011, Andhra Pradesh, commenced commercial production in 2021.
The Company acquired 487000 additional stake in Sequent Penems Private Limited, subsidiary company and subsequently Sequent Pharma became the wholly owned subsidiary of Company effective from April 27, 2021. In 2024, the Company sold its entire shareholding in Sequent Penems Private Limited to Symbio Generrics India Private Limited and Sequent Penems Private Limited ceased to be a subsidiary of the Company with effect from April 25, 2024.
The wholly owned entity, Synthix Global Pharma Solutions Limited has got incorporated on April 29, 2025.
.
Solara Active Pharma Sciences Ltd share price is for NSE ₹ 592.90 & for BSE ₹ 594.00 as on Dec 15 2025 03:30 PM.
The market cap of Solara Active Pharma Sciences Ltd for NSE ₹ 2,849.06 & for BSE ₹ 2,854.35 as on Dec 15 2025 03:30 PM.
The 52 Week High and Low of Solara Active Pharma Sciences Ltd for NSE is ₹ 766.45 and ₹ 442.80 and for BSE is ₹ 767.45 and ₹ 441.10.
The 1 year returns on the stock has been -20.85%.
As on Dec 15 2025 03:30 PM the price-to-earnings (PE) ratio for Solara Active Pharma Sciences Ltd share is 584.16.
As on Dec 15 2025 03:30 PM, the price-to-book (PB) ratio for Solara Active Pharma Sciences Ltd share is 345.21.
You can trade in Solara Active Pharma Sciences Ltd shares with Bajaj Broking by opening a demat account.
To buy Solara Active Pharma Sciences Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Solara Active Pharma Sciences Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found
